IL18 and atherosclerosis: The multifaceted etiology of atherosclerosis, the pleiotropic effects of the current oral lipid-lowering drugs, and the still not fully elucidated impact of inclisiran on the different pathogenetic factors in atherosclerosis have led us to explore its influence on the subclinical inflammatory markers of the disease i.e., PTX3, IL-18, and the soluble cluster of differentiation 40 ligand (sCD40L).